首页> 外文期刊>臨床血液 >Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma
【24h】

Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma

机译:恶性淋巴瘤化疗后通过骨髓增生异常综合征发展为与治疗相关的急性骨髓性白血病(AML-M6),并具有add(11)(q23)和del(20)(q11.2)

获取原文
获取原文并翻译 | 示例
       

摘要

A 62-year-old woman was diagnosed as having malignant lymphoma, diffuse large B-cell type. She underwent chemotherapy with the standard dose of CHOP and MINE regimens, resulting in complete remission. Four months later, the myelodysplastic syndrome of RA (refractory anemia) with pancytopenia developed and rapidly progressed to acute myelogenous leukemia (AML-M6) in 4 months. Cytogenetic analysis for the bone marrow specimens of both periods of MDS and AML-M6 revealed complex karyotypic abnormalities involving chromosome 5, 7, 11q23 and 20q11.2. Neither rearrangement of the MLL gene by Southern blot analysis nor tandem duplication of MLL gene by RT-PCR technique was detected. The patient was died from progression of leukemia and pneumonia. The autopsy showed no residual disease of lymphoma-related disease.
机译:一名62岁的妇女被诊断患有恶性淋巴瘤,弥漫性大B细胞型。她接受了标准剂量的CHOP和MINE方案化疗,从而完全缓解。 4个月后,伴有全血细胞减少的RA(难治性贫血)骨髓增生异常综合征在4个月内发展为急性骨髓性白血病(AML-M6)。对MDS和AML-M6两个时期的骨髓标本进行细胞遗传学分析,发现复杂的核型异常,涉及染色体5、7、11q23和20q11.2。通过Southern印迹分析未检测到MLL基因的重排,也未通过RT-PCR技术检测到MLL基因的串联重复。该患者因白血病和肺炎的进展而死亡。尸检未发现淋巴瘤相关疾病的残留病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号